Haisco's $1.5B Deal with US Venture Signals New Era for Chinese Pharma

BEIJING, China – August 25, 2026 – In a landmark transaction that underscores the shifting dynamics of global pharmaceutical innovation, China's Haisco Pharmaceutical Group has entered into an exclusive licensing agreement worth over $1.5 billion with Sentivera, a new US venture backed by powerhouse investors Population Health Partners (PHP) and ARCH Venture Partners. The deal grants Sentivera global rights to a promising preclinical immunology drug, marking one of the most significant endorsements of Chinese-developed medicine to date and heralding a new, more integrated era of cross-border biotech collaboration.

Under the terms announced Tuesday, Haisco will receive an upfront payment and equity consideration totaling $75.89 million, with the potential for an additional $1.46 billion in development, regulatory, and commercial milestone payments. The agreement, which excludes the Greater China market, also includes tiered royalties on future net sales. This move not only provides a substantial non-dilutive infusion of capital for Haisco but also positions it as a key player in the global fight against inflammatory diseases.

A New Blueprint for Biotech Partnerships

Beyond its staggering financial potential, the deal is turning heads for its innovative structure. Rather than a traditional license-out transaction, Haisco and its partners have opted for a 'Newco partnership structure.' Sentivera was purpose-built by ARCH and PHP to develop this specific asset. As part of the deal, Haisco receives a significant 17.5% equity stake in the new company, on top of a $40 million cash upfront payment.

This model represents a strategic evolution in how biotech collaborations are formed. It transforms Haisco from a passive licensor into an active partner with vested interest in the long-term success of the drug. Haisco stated that this structure enables "deeper strategic alignment and shared growth with Sentivera and its investors, marking an upgrade in Haisco's global expansion strategy." The Newco model effectively de-risks the costly late-stage development for Haisco by leveraging the capital and specialized expertise of its US partners, while allowing it to retain significant upside potential through its equity position.

This hybrid approach is rapidly gaining favor, particularly for cross-border deals originating from China. Industry analysis shows that over 20 such Newco entities have been formed since early 2025, as Chinese firms seek more sophisticated ways to access global capital markets and operational expertise. By spinning out a high-potential asset into a focused, well-funded US entity, Haisco can accelerate its global development while concentrating internal resources on its broader R&D pipeline.

The Rising Tide of Chinese Innovation

The Haisco-Sentivera agreement is not an isolated event but a powerful symbol of a much larger trend: the dramatic ascent of China as a source of global pharmaceutical innovation. For years, the narrative was centered on "Made in China," but it has decisively shifted to "Created in China." A confluence of factors—including sweeping regulatory reforms since 2015, a deep talent pool, and significant cost and speed advantages in R&D—has created a fertile ecosystem for groundbreaking science.

The results are striking. In the first half of 2026 alone, Chinese companies inked a record-breaking 81 out-licensing deals with overseas partners, with a total potential value of $110 billion. This explosion in activity has seen China's share of global out-licensing deals jump from just 5% in 2020 to 32% in the first half of 2025, according to industry reports.

Haisco itself is at the forefront of this movement. The Sentivera deal is the latest in a string of high-value partnerships for the company this year. In June, it announced a collaboration with Eli Lilly for five early-stage programs potentially worth up to $3 billion. That same month, it struck a deal with Nuvectis for two late-stage assets valued at over $1.4 billion. This followed a $715 million global licensing agreement with AbbVie in April for a preclinical pain asset. This consistent deal-making prowess demonstrates that Haisco's R&D engine is producing a portfolio of assets highly sought after by major global pharmaceutical players, validating its long-term strategy of investing over 15% of its revenue back into research.

Targeting Inflammation with Top-Tier Backing

At the heart of the deal is a preclinical, orally administered small-molecule drug designed to treat type 2 inflammatory diseases. This category includes widespread and often debilitating conditions such as atopic dermatitis (eczema), asthma, and chronic rhinosinusitis. The asset, which received Investigational New Drug (IND) approval in China this month, has shown strong anti-inflammatory activity and a favorable safety profile in preclinical studies. While incumbents like Sanofi and Regeneron's Dupixent have established a strong presence in the market, a significant unmet need remains for new, effective, and potentially more accessible treatments.

The formation of Sentivera is backed by two of the most respected names in life sciences venture capital. ARCH Venture Partners has a four-decade history of building disruptive, science-driven companies, while Population Health Partners focuses specifically on creating ventures to tackle prevalent diseases and extend human healthspan. The duo previously co-founded the anti-obesity biotech Metsera, a venture that achieved remarkable success, underscoring their ability to identify promising science and build world-class development teams around it.

Their involvement provides more than just capital; it is a powerful vote of confidence in the scientific merit of Haisco's drug candidate. By placing the asset in the hands of a dedicated team with a proven track record, the collaboration aims to navigate the complex global regulatory and clinical landscape efficiently, accelerating its path to patients worldwide who are in need of better therapeutic options.